All patients
adolescents (typically 12-15 years of age) adults (typically between 18 and 65yr) age >= 55 yr age >= 60 yr age >= 65 yr age >= 75 yr alpha variant (B.1.1.7, UK) any cancer autoimmune disease beta variant (B.1.351 / 501Y.V2, South Africa) children corticosteroids: no corticosteroids: yes critical disease delta variant (B.1.617.2, Indian) dialysis patients elderly (typically over 65yr) fully vaccinated gamma variant (P.1, Brazil) haematological cancers healthcare workers immunodepression invasive ventilation kidney transplant recipients no oxygen needed non invasive oxygen obese omicron variant BA.1 (B.1.1.529) omicron variant BA.2 VOC original (Wuhan) strain positive for SARS-Cov-2 at baseline severe disease solid cancer solid organ transplant recipients subjects at risk
potential COVID-19 treatments in COVID-19 prophylaxis (excluding children) - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias deathsdetailed results ChAdOx1 phase 3 (AstraZeneca), 2020 0.20 [0.02; 1.72]
0.20 [0.02 ; 1.72 ] ChAdOx1 phase 3 (AstraZeneca), 2020 1 0% 11,636 NA not evaluable symptomatic Covid-19detailed results ChAdOx1 phase 3 (AstraZeneca), 2020 0.33 [0.26; 0.43]
0.33 [0.26 ; 0.43 ] ChAdOx1 phase 3 (AstraZeneca), 2020 1 0% 17,177 NA not evaluable asymptomatic COVID casedetailed results ChAdOx1 phase 3 (AstraZeneca), 2020 0.33 [0.23; 0.48]
0.33 [0.23 ; 0.48 ] ChAdOx1 phase 3 (AstraZeneca), 2020 1 0% 11,636 NA not evaluable infection (PCR positive symptomatic or not)detailed results ChAdOx1 phase 3 (AstraZeneca), 2020 0.44 [0.33; 0.59]
0.44 [0.33 ; 0.59 ] ChAdOx1 phase 3 (AstraZeneca), 2020 1 0% 11,636 NA not evaluable severe COVID-19 occurrencedetailed results ChAdOx1 phase 3 (AstraZeneca), 2020 0.49 [0.02; 14.54]
0.49 [0.02 ; 14.54 ] ChAdOx1 phase 3 (AstraZeneca), 2020 1 0% 23,745 NA not evaluable vaccine efficacy after dose 1 (and before dose 2)detailed results ChAdOx1 phase 3 (AstraZeneca), 2020 0.24 [0.14; 0.41]
0.24 [0.14 ; 0.41 ] ChAdOx1 phase 3 (AstraZeneca), 2020 1 0% 18,494 NA not evaluable serious adverse eventsdetailed results ChAdOx1 phase 3 (AstraZeneca), 2020 0.86 [0.64; 1.17]
0.86 [0.64 ; 1.17 ] ChAdOx1 phase 3 (AstraZeneca), 2020 1 0% 23,745 NA not evaluable Bell's palsydetailed results ChAdOx1 phase 3 (AstraZeneca), 2020 0.98 [0.20; 4.83]
0.98 [0.20 ; 4.83 ] ChAdOx1 phase 3 (AstraZeneca), 2020 1 0% 23,745 NA not evaluable immediate allergic reactiondetailed results ChAdOx1 phase 3 (AstraZeneca), 2020 1.95 [0.07; 58.15]
1.95 [0.07 ; 58.15 ] ChAdOx1 phase 3 (AstraZeneca), 2020 1 0% 23,745 NA not evaluable multiple sclerosisdetailed results ChAdOx1 phase 3 (AstraZeneca), 2020 1.95 [0.07; 58.15]
1.95 [0.07 ; 58.15 ] ChAdOx1 phase 3 (AstraZeneca), 2020 1 0% 23,745 NA not evaluable myelitisdetailed results ChAdOx1 phase 3 (AstraZeneca), 2020 1.95 [0.18; 21.52]
1.95 [0.18 ; 21.52 ] ChAdOx1 phase 3 (AstraZeneca), 2020 1 0% 23,745 NA not evaluable Potential Immune Gastrointestinal disordersdetailed results ChAdOx1 phase 3 (AstraZeneca), 2020 0.33 [0.03; 3.13]
0.33 [0.03 ; 3.13 ] ChAdOx1 phase 3 (AstraZeneca), 2020 1 0% 23,745 NA not evaluable Potential Immune Musculoskeletal disordersdetailed results ChAdOx1 phase 3 (AstraZeneca), 2020 0.98 [0.06; 15.60]
0.98 [0.06 ; 15.60 ] ChAdOx1 phase 3 (AstraZeneca), 2020 1 0% 23,745 NA not evaluable Potential Immune Neuroinflammatory disordersdetailed results ChAdOx1 phase 3 (AstraZeneca), 2020 1.22 [0.33; 4.54]
1.22 [0.33 ; 4.54 ] ChAdOx1 phase 3 (AstraZeneca), 2020 1 0% 23,745 NA not evaluable Potential Immune Skin disordersdetailed results ChAdOx1 phase 3 (AstraZeneca), 2020 0.73 [0.16; 3.27]
0.73 [0.16 ; 3.27 ] ChAdOx1 phase 3 (AstraZeneca), 2020 1 0% 23,745 NA not evaluable Potential Immune Vasculitidesdetailed results ChAdOx1 phase 3 (AstraZeneca), 2020 0.49 [0.02; 14.54]
0.49 [0.02 ; 14.54 ] ChAdOx1 phase 3 (AstraZeneca), 2020 1 0% 23,745 NA not evaluable Thromboembolic eventsdetailed results ChAdOx1 phase 3 (AstraZeneca), 2020 0.49 [0.15; 1.62]
0.49 [0.15 ; 1.62 ] ChAdOx1 phase 3 (AstraZeneca), 2020 1 0% 23,745 NA not evaluable 0.0 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-04 21:52 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 89
- treatments: 290,547,608,830,831,829,901,680,595,828,681,1209,833,629,689,543,617,625,859,511,960,546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525,843,827,1047,1048,819,545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814,649,650,589,651,968,1245,610,751,747,695,548,970,594,565,879,1257,571,626,697,572,1234,586,573,540,592,930,949,838,698,934,735,929,948,946,945,587,655,1146,531,933,613,919,725,678,921,621,959,748,1348,1256,924,1243,925,658,699,612,552,590,891,605,892,722,618,609,551,834,763,922,935,620,1317,1265,824,766,857,1291,1088,1331,1330,1329,1344,1328,1327,979,822,762,805,950,757,761,806,758,826,755,821,1288,1287,1286,760,1284,802,765,1285,759,823,804,1264,764,858,835,1262,1290,1316,1341,1342,1343,825,803,1244,523,885,734,1439
- roots T: 290
